Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review

Lucid Diagnostics (NASDAQ:LUCD) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Lucid Diagnostics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Lucid Diagnostics and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,069.87%	N/A	-123.54%
Insulet	21.22%	27.98%	9.16%

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Lucid Diagnostics and Insulet, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	0	0	4	1	3.20
Insulet	0	2	13	0	2.87

Lucid Diagnostics presently has a consensus price target of $3.63, suggesting a potential upside of 148.29%. Insulet has a consensus price target of $277.13, suggesting a potential downside of 1.22%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Insulet.

Earnings & Valuation

This table compares Lucid Diagnostics and Insulet”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$2.43 million	35.65	-$52.67 million	($1.14)	-1.28
Insulet	$1.70 billion	11.60	$206.30 million	$5.84	48.04

Insulet has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

Insulet beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.